Neuromyelitis Optica Spectrum Disorder (Device’s Disease): - A Case Report Of Full Recovery With Corticosteroids, Therapeutic Plasmapheresis And Immunotherapy COVID VACCINE UNRAVELLING THE DEVIC’S WITHIN

Main Article Content

Dr. Raghavi A. Bembey
Dr. Aman Singla
Dr. Ram Babu


Neuromyelitis optica is a severely disabling inflammatory disorder of autoimmune etiology of the central nervous system, mainly affecting the optic nerves and spinal cord. Here, we present a case report of neuromyelitis optica in a 28-year-old Indian woman who presented with sudden painless loss of vision with tingling followed by weakness of all four limbs with bowel involvement that developed over a period of one week, with a significant history of recent vaccination with COVISHIELD (ChAdOx1 nCoV- 19) vaccine . Clinical evaluation showed diminished vision in both eyes, which progressed to loss of power across all major muscle groups in all limbs and bowel involvement. Magnetic resonance imaging of brain with contrast was done which showed T2W/FLAIR hyperintense non enhancing signal in bilateral thalami extending caudally in mid brain on left side and in midline anterior medulla with subtle T2 hyperintense signal in body of corpus callosum, similar foci are seen in bilateral frontoparietal white matter suggestive of ADEM or demyelination. Also T2 hyperintense signal in both optic nerves [left> right] in posterior part of orbit suggestive of optic neuritis. MRI whole spine showed multiple patchy hyperintense signals on T2 and hypointensity on T1 all over cervical and dorsal vertebrae through whole segment in contiguous manner. The patient was immediately started on intravenous methylprednisolone pulse therapy followed by plasmapheresis and immunomodulator therapy. The diagnosis of neuromyelitis optica was later confirmed with strongly positive neuromyelitis optica immunoglobulin G. Since, treatment was started early patient responded very well and made full recovery. Hence, early initiation of aggressive immunosuppressive treatment is essential in such cases.

Article Details

How to Cite
Bembey, D. R. A., Singla, D. A. and Babu, D. R. (2023) “Neuromyelitis Optica Spectrum Disorder (Device’s Disease): - A Case Report Of Full Recovery With Corticosteroids, Therapeutic Plasmapheresis And Immunotherapy: COVID VACCINE UNRAVELLING THE DEVIC’S WITHIN”, International Journal of Integrated Medical Research, 10(03), pp. 95–101. doi: 10.57181/ijoimr/vol10i03/120.
Case Report


D. M. Wingerchuk, W. F. Hogancamp, P. C. O'Brien, and B. G. Weinshenker, “The clinical course of neuromyelitis optica (devic's syndrome),” Neurology, vol. 53, no. 5, pp. 1107–1114, 1999.

K. Yamasaki, J.-I. Kira, T. Kanai et al., “Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders,” Annals of Neurology, vol. 40, no. 4, pp. 569–574, 1996.

D. M. Wingerchuk, B. Banwell, J. L. Bennett et al., “International consensus diagnostic criteria for neuromyelitis optica spectrum disorders,” Neurology, vol. 85, no. 2, pp. 177–189, 2015.

D. M. Wingerchuk and B. G. Weinshenker, “Neuromyelitis optica,” Current Treatment Options in Neurology, vol. 10, no. 1, pp. 55–66, 2008.

Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, et al. EFNS guidelines on diagnosis and management of neuromyelitis. Eur J Neurol 2010; 17: 1019-32.

Saikali P, Cayrol R, Vincent T. Anti-aquaporin-4 autoantibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun Rev 2009; 9: 132-5.

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-12.

Min JH, Kim HJ, Kim BJ, Lee KW, Sunwoo IN, Kim SM, et al. Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Mult Scler 2009; 15: 1069-76.

Mc Keon, Lennon VA, Jacob A, Matiello M, Lucchinetti CF, Kale N, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 2009; 39: 87-90.

Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patient. Arch Neurol 2009; 66: 1128-33.

Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-8.